24/7 Market News – (NASDAQ: BCTX) BriaCell Therapeutics Corp. shares are moving higher at the open up more than 4.8% on more than 1,400 trades at $5.92 the company was published this morning in a leading journal.
• Anti-Cancer activity of BriaCells lead candidate, Bria-IMT, in advanced breast cancer patients was published in a leading peer-reviewed publication.
• Bria-IMT, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria-IMT HLA types, supporting BriaCells platform strategy of developing off-the-shelf personalized immunotherapy for multiple cancer indications.
• The clinical data, previously reported, included rapid tumor reduction and extended survival.
PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq:BCTX, BCTXW) (TSX:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCells lead candidate, Bria-IMT. The abstract of the paper was published on-line in Recent Patents on Anti-Cancer Drug Discovery, a publication focused on research (where patents have been registered) in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery. The publication highlights BriaCells approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action. The full text of the article will be made available.
• The clinical data, previously reported, included rapid tumor reduction and extended survival.
PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq:BCTX, BCTXW) (TSX:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCells lead candidate, Bria-IMT. The abstract of the paper was published on-line in Recent Patents on Anti-Cancer Drug Discovery, a publication focused on research (where patents have been registered) in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery. The publication highlights BriaCells approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action. The full text of the article will be made available.